HOSPITAL UNIVERSITARIO QUIRÓNSALUD MADRID
Departamento
University of Chicago
Chicago, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Chicago (3)
2019
-
Cost of achieving hba1c and weight loss treatment targets with ideglira vs insulin glargine u100 plus insulin aspart in the usa
ClinicoEconomics and Outcomes Research, Vol. 11, pp. 271-282
-
IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy
Diabetes, Obesity and Metabolism, Vol. 21, Núm. 12, pp. 2643-2650
2018
-
Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: The dual VII randomized clinical trial
Diabetes Care, Vol. 41, Núm. 5, pp. 1009-1016